FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200586895> ?p ?o ?g. }

• W3200586895 endingPage "305" @default.
• W3200586895 startingPage "305" @default.
• W3200586895 abstract "305 Background: Nivolumab plus ipilimumab (NIVO+IPI), a first-in-class combination immunotherapy, was approved by the US Food and Drug Administration in April 2018 for the treatment of intermediate- or poor-risk advanced renal cell carcinoma (RCC), and the treatment paradigm has changed dramatically over the past few years. This real-world study examined treatment patterns and sequences, treatment response, safety, and survival outcomes with this novel first-line (1L) combination therapy among patients diagnosed with metastatic RCC (mRCC) in a community oncology practice setting. Methods: A retrospective analysis of the US Oncology Network’s iKnowMed medical data examined adult patients with an International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognosis of intermediate- or poor-risk clear cell mRCC who received 1L NIVO+IPI between April 1, 2018, and March 31, 2020. Baseline demographic and clinical characteristics, treatment patterns, and treatment sequence were examined descriptively. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), time to treatment discontinuation (TTD), and time to treatment response (TTR) were analyzed using the Kaplan–Meier method. Treatment-related adverse events (TRAEs) and healthcare resource utilization were also analyzed. Results: A total of 193 adults with stage IV mRCC treated with 1L NIVO+IPI were identified. Median age (range) was 63 (30.0–89.0) years, 73.1% were male, 69.4% were white, 56.7% were IMDC intermediate risk, and 60.6% had a documented Eastern Cooperative Oncology Group performance status of 0 or 1. Median follow-up time (range) was 9.7 (0.1–24.7) months. Median PFS (95% CI) was 17.1 (12.6–21.2) months, and the 1-year landmark PFS rate was 58.3% (50.4–65.4). At 12 months, the OS rate (95% CI) was 75.4% (67.8–81.4). The ORR (95% CI) was 43.2% (34.6–52.1) among patients with a response assessment; the median TTR (range) was 2.8 (0.3–4.1) months and median DoR was not reached. Median TTD (95% CI) was 5.8 (4.5–7.5) months. Among the 63 (31.3%) patients who received second-line therapy, 50.8% received cabozantinib and 12.7% received pazopanib. TRAEs were reported in 47.2% of patients—the most frequently reported were fatigue (13.5%), rash (10.4%), diarrhea (6.7%), nausea (6.2%), colitis (3.6%), and pruritus (3.6%). The treatment-related hospitalization rate was 5.5% and the emergency department visit rate was 3.1%. Conclusions: This real-world study supports the clinical efficacy of 1L NIVO+IPI for patients with mRCC. Our findings also suggest that the NIVO+IPI combination was generally well tolerated in the real-world setting, with low rates of adverse events and healthcare resource utilization." @default.
• W3200586895 created "2021-09-27" @default.
• W3200586895 creator A5001330237 @default.
• W3200586895 creator A5009558038 @default.
• W3200586895 creator A5013217019 @default.
• W3200586895 creator A5025170069 @default.
• W3200586895 creator A5033372450 @default.
• W3200586895 creator A5072267835 @default.
• W3200586895 creator A5075481530 @default.
• W3200586895 creator A5090867847 @default.
• W3200586895 date "2021-10-01" @default.
• W3200586895 modified "2023-10-16" @default.
• W3200586895 title "Real-world outcomes in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab." @default.
• W3200586895 doi "https://doi.org/10.1200/jco.2020.39.28_suppl.305" @default.
• W3200586895 hasPublicationYear "2021" @default.
• W3200586895 type Work @default.
• W3200586895 sameAs 3200586895 @default.
• W3200586895 citedByCount "2" @default.
• W3200586895 countsByYear W32005868952023 @default.
• W3200586895 crossrefType "journal-article" @default.
• W3200586895 hasAuthorship W3200586895A5001330237 @default.
• W3200586895 hasAuthorship W3200586895A5009558038 @default.
• W3200586895 hasAuthorship W3200586895A5013217019 @default.
• W3200586895 hasAuthorship W3200586895A5025170069 @default.
• W3200586895 hasAuthorship W3200586895A5033372450 @default.
• W3200586895 hasAuthorship W3200586895A5072267835 @default.
• W3200586895 hasAuthorship W3200586895A5075481530 @default.
• W3200586895 hasAuthorship W3200586895A5090867847 @default.
• W3200586895 hasConcept C121608353 @default.
• W3200586895 hasConcept C126322002 @default.
• W3200586895 hasConcept C143998085 @default.
• W3200586895 hasConcept C2777472916 @default.
• W3200586895 hasConcept C2777701055 @default.
• W3200586895 hasConcept C2778715236 @default.
• W3200586895 hasConcept C2780030458 @default.
• W3200586895 hasConcept C2781433595 @default.
• W3200586895 hasConcept C71924100 @default.
• W3200586895 hasConceptScore W3200586895C121608353 @default.
• W3200586895 hasConceptScore W3200586895C126322002 @default.
• W3200586895 hasConceptScore W3200586895C143998085 @default.
• W3200586895 hasConceptScore W3200586895C2777472916 @default.
• W3200586895 hasConceptScore W3200586895C2777701055 @default.
• W3200586895 hasConceptScore W3200586895C2778715236 @default.
• W3200586895 hasConceptScore W3200586895C2780030458 @default.
• W3200586895 hasConceptScore W3200586895C2781433595 @default.
• W3200586895 hasConceptScore W3200586895C71924100 @default.
• W3200586895 hasFunder F4320307115 @default.
• W3200586895 hasIssue "28_suppl" @default.
• W3200586895 hasLocation W32005868951 @default.
• W3200586895 hasOpenAccess W3200586895 @default.
• W3200586895 hasPrimaryLocation W32005868951 @default.
• W3200586895 hasRelatedWork W2792937256 @default.
• W3200586895 hasRelatedWork W2794528692 @default.
• W3200586895 hasRelatedWork W2966932534 @default.
• W3200586895 hasRelatedWork W2977436503 @default.
• W3200586895 hasRelatedWork W2981065291 @default.
• W3200586895 hasRelatedWork W3118891956 @default.
• W3200586895 hasRelatedWork W3152520552 @default.
• W3200586895 hasRelatedWork W4283731517 @default.
• W3200586895 hasRelatedWork W4310753920 @default.
• W3200586895 hasRelatedWork W4362587156 @default.
• W3200586895 hasVolume "39" @default.
• W3200586895 isParatext "false" @default.
• W3200586895 isRetracted "false" @default.
• W3200586895 magId "3200586895" @default.
• W3200586895 workType "article" @default.